Navigation Links
Researchers Evaluate Computer-based Treatment for People with Schizophrenia
Date:6/27/2012

SAN FRANCISCO, June 27, 2012 /PRNewswire/ -- Researchers at San Francisco-based Brain Plasticity, Inc. (BPI) have begun a multi-center study to evaluate the effects of a computerized, brain-plasticity-based program designed to address the cognitive issues associated with schizophrenia.  The clinical trial, e-CAeSAR (Evaluation of a Cognitively Adaptive e-treatment in Schizophrenia-diagnosed Adults:  A Remediation-based Approach), is being funded by the National Institute of Mental Health (NIMH) and will be conducted at eleven research centers in the U.S. in collaboration with experienced investigators from the Schizophrenia Trials Network (STN).

Cognitive impairment is a devastating component of schizophrenia that affects virtually all persons who are diagnosed.  The NIMH estimates that nearly 40 percent ($44 billion) of schizophrenia's total cost involves lost time from work for patients and care providers, and places high demands on social services.  This makes schizophrenia the most costly mental illness in the United States.

The "e-CAeSAR" trial is the first time neuroscientists will work with U.S. Food and Drug Administration representatives to evaluate Brain Plasticity's program.  Pharmaceutical companies have tested drugs in development to alleviate the cognitive symptoms of schizophrenia; thus far none have been FDA-approved as efficacious. 

"Cognitive impairment in schizophrenia sorely needs attention, yet there are no FDA-approved treatments for this devastating aspect of the illness," notes Dr. Richard Keefe of the Schizophrenia Trials Network (STN).  These cognitive impairments can limit the ability of persons with schizophrenia to process new information accurately and quickly, make effective decisions and remember key information.  Coupled together, these symptoms can severely impair patients' abilities to perform everyday activities, live independently, gain employment and sustain social relationships. It is commonly believed that the most significant symptoms of schizophrenia are delusions and/or hallucinations, yet these represent only a fraction of the symptoms.

"We are honored to work with world-renowned researchers who are part of the Schizophrenia Trials Network.  We hope that our efforts encourage other scientists to develop and study new cognitive treatments to support persons with schizophrenia and their families," states BPI Chief Operating Officer Dr. Henry Mahncke.

"We are excited to participate in this long-awaited, much-needed seminal trial of cognitive remediation for individuals with schizophrenia. Cognitive remediation is a potential breakthrough treatment that along with more traditional pharmaceutical and psychotherapeutic modalities may significantly impact the lives of those living with schizophrenia, their families and society as a whole, said Jennifer Hoblyn, MD, MPH, who directs Inpatient Mental Health Services at the Veterans Affairs Medical Center in Palo Alto, CA., an investigator in the e-CAeSAR study. 

About Brain Plasticity Incorporated

Brain Plasticity, Inc., was founded in 2009 to support the rapid development and evaluation of innovative neuroscience-based brain health solutions. For more information, visit www.brainplasticity.com or contact Henry Mahncke, PhD, at 415.394.3107.

Media Contact:

Peggy Jara

Harden Communications Partners

510-635-4150

pjara@hardenpartners.com


'/>"/>
SOURCE Brain Plasticity, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Rethinking Research Ethics: Carnegie Mellon and McGill Researchers Challenge Post-marketing Trial Practices
2. Van Andel Institute Researchers Find Potential Drug Target For Aggressive Form Of Lymphoma
3. EvaluatePharma Names Debbie Paul CEO, Americas to Lead Growth in Key Region
4. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
5. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
6. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
7. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
8. Elekta, pioneer in treatment of cancer in brain disorders, to Move North America Headquarters to Atlanta
9. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
10. National Patient Advocate Foundation Praises Signing of the Delaware Cancer Treatment Access Act into Law
11. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... Calif. , April 28, 2016  Marking ... widely accessible breast and ovarian cancer risk test, ... panel analyzing 30 genes that highly impact the ... women. Available today, the Color Test analyzes hereditary ... prostate, stomach, and uterine cancers. The Color Test ...
(Date:4/28/2016)... April 28, 2016  The blood testing market in ... according to Kalorama Information and The Freedonia Group in ... nucleic acid testing.  The healthcare research firm said that ... developing blood collection stations and in improving testing at ... Information,s report, Blood Testing Market in China ...
(Date:4/28/2016)... , Net Sales of $1.90 billion represent an increase ... period, and an increase of 1.2% on an adjusted pro ... first quarter were $0.52 reported, a decrease of 47.5% from ... 29.9% over the prior year period , The Company ... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) ...
Breaking Medicine Technology:
(Date:4/29/2016)... Texas (PRWEB) , ... April 29, 2016 , ... Spine ... neck pain, is proud to announce one of their physicians has been invited to ... Family Physicians (Texas ACOFP) Family Practice Review conference on April 30, 2016. , ...
(Date:4/29/2016)... ... 29, 2016 , ... The Gluten-Free Certification Program (GFCP), in ... the launch of the GFCP Scoop in response to consumer demand ... the GFCP Scoop site is to keep the gluten-free community updated ...
(Date:4/29/2016)... ... ... Reltok Nasal Products proudly announces that Boston Medical Products, Inc., a leading ... specialty, has added the KOTLER NASAL AIRWAY™ to its diverse product line. , A ... safety device secured by nasal surgeons onto the floor of the nasal passages, at ...
(Date:4/29/2016)... ... April 29, 2016 , ... Regenerative Medicine Solutions ... Work employee satisfaction survey, earning them second place for Tampa’s Best Places to Work. ... , “This is a great accomplishment for our team,” says RMS Human Resources ...
(Date:4/29/2016)... ... April 29, 2016 , ... Natren, Inc. recently ... of probiotics, Petbiotics ™, as they fondly call them. As animal lovers, ... networking for their non-profit organizations. Animal rescues across the nation face huge hurdles ...
Breaking Medicine News(10 mins):